PANCREASCANCERconsultJan2025||68Fwithjaundice+abdom1na1pain+weightioss~presentingER01/05/2025CTshowed§4.8cmmassHEADofpancreas+dilatedbi1iaryduct+portaIvein~involvement

ERCP:b1iiarystent~placed01/08/2025bi1irubindecreasedfrom8.2to2.1mg/dL

Endoscop1cU1trasound+FNAb1opsy01/10/2025:PANCREATICDUCTALADENOCARCINOMA,poor1ydifferent1atedCA19-9:1240U/mL(markedlyelevated)

STAGING~imaging:CTchest/abdomen/pe1vis01/15/2025mass:4.8cmheadpancreas,encasingSMA>180degrees,abuttingportaIvein,contactceIiacaxis<180degreesLymphnodesperiipancreatic+ceIiac+portahepatis=enlarged2liver1esionssuspiciousmetsstage§cT4N1M1,StageIV(BORDERLINERESECTABLE?actuallyUNRESECTABLEduetoSMAencasement+1ivermets)

MoIecularNGSpanel(Tempus~xT)01/20/2025KRAS§G12Vmutation(VAF58%)TP53~R175Hmut(VAF62%)CDKN2A~homo~deletionSMAD4§1oss~BRCA1:negBRCA2:pathogen1cGERMLINEvariantc.8537_8538de1AG(p.Glu2846fs)~fami1yh1story:sister~breastca~age42motherovarianca52MSI:MSSdMMR:pMMRTMB:5mut/MbPDL1:CPS<1

Patientevaluation:ECOG3(>50%bed-bound,1imitedselfcare)weight~1oss:22lbs/3monthspa1n:severe~8/10requiringoxycodonel0mgQ4hoursbi1irubinnormaIizedafterERCPstentCA19-9:1240jaundice:reso1ved~butpersistentpruritis

GLUCOSEcontro1:newonsetdiabetesmellitus~HbA1c8.2%started1nsu1intherapy(diabetes§secondary~topancreaticcancerdestruction)

TREATMENTPLAN:EnrolledinSWOG-S1505trial(NCT02562716)mF0LF1R1N0X+durva1umab(chemother apy+immun0therapy)vscontrolarmRandomized:ARMA(experimentalarm~immun0combo)Start:02/01/2025

Cyc1e1(Feb2025):to1eratedpoorly~Grade3nausea/vomiting,Grade2peripheraineuropathy,Grade1fatigue,hospita1izedfor3daysIVhydration+ant1-emeticsWeight:continued~dec1ining~lost8morepoundsCyc1e2DELAYED1weekduetopoorperformance

Cyc1e2(March2025):Grade2rash(immune-re1ated?)suspected~immunetherapytoxicitystero1dsstarted(prednisone0.5mg/kg)continuechemoonlyGrade3thr0mbocytopenia~p1atelets42K~0xalip1atinHELD

RestagingCT04/2025:PR0GRESS10Nmass:6.1cm(was4.8cm)newliver~mets:4lesions(were2)ascites:new~moderateCA19-9:3680U/mL(increasedfrom1240)

Patientw1thdrawfromtrial04/15/2025duetoprogression+intolerabi1ity

PALLIAT1VEconsult:pa1nesca1ation~fentany1patch75mcgQ72hrs+oxycodonebreakthroughPS:nowECOG4(comp1etelybed-bound)

SECONDL1NE:Started11po~somalirinotecannon0110(05/01/2025)~PEP-02trial(NCT01494506)vs~gemcitabine+nabpac1itaxe1RANDOM1ZED:nanoliposoma1irinotecanarm

Cyc1e1-2(May-June2025):minimal~toxicityGrade1diarrhea0nlyPA1Nimproved~fentanylreducedto50mcg

RestagingCT07/2025:STABLED1SEASEmass:6.0cm(s1ightdecrease)liver:4lesions~stab1esizesascites:mi1d(improved)CA19-9:2100U/mL(decreased!)

Cyc1e5(Sept2025):deve10pedGrade3b111arysepsis~stent~0CCLUS10Nhospita1izedforERCP+stentrep1acement+IV~antibiotics(piperacillin-tazo~bactam)5daysICU

Postrecovery~continuedinano1iposoma1irinotecanCyc1e7(0ct2025):b10odstestshowed:b1lirubinagaine1evated3.8~stentmai~function?CA19-9:rising~4200U/mL

NextCT11/2025:MIXEDRESPONSEPROGRESS10Nmass:stable~6.1cm1iver:2lesionsincreaseds1ze(segment5:from2.1cmto3.8cm,segment8:1.4to2.9cm)2lesionsstableoligoprogression

Discussedwithpatient+family:poorprognosis,consideringbestsupp0rtivecare~vs~clinicaltrial~THlRDLlNEopt1on~notavailable~bestsupp0rtivecaredecidedbypatient§Hospiceenrollment12/01/2025
